Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million
Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately.
On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.
The deal came less than a week after Emergent (NYSE: EBS) announced it would buy French pharmaceutical giant Sanofi's sma llpox vaccine business in an all-cash deal worth up to $125 million.
"People have been waiting for acquisitions from…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Tina Reed Source Type: news
More News: Anthrax | Anthrax Vaccine | France Health | Health Management | Mergers and Aquisitions | Pharmaceuticals | Vaccines